drugset / Trial / NCT02182570

WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients

NCT02182570

Phase 3 Completed 62 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

The safety and efficacy of WAL 801 CL (epinastine hydrochloride) Dry Syrup in the treatment of atopic dermatitis in children was evaluated and plasma drug concentrations were measured.

Timeline

Start
2001-06
Primary completion
2002-02
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule

Indications